<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818970</url>
  </required_header>
  <id_info>
    <org_study_id>TPL001-01</org_study_id>
    <nct_id>NCT04818970</nct_id>
  </id_info>
  <brief_title>Adaptive Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients</brief_title>
  <official_title>Adaptive Photo-Protection Trial: To Demonstrate the Safety and Efficacy of NB-UVB Light Therapy to Improve Outcomes in Hospitalized High-risk Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokind, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cytokind, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to evaluate the translational application of the safe and effective&#xD;
      treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in&#xD;
      an effort to improve their immune and hemostatic imbalance to increase survival and improve&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design&#xD;
&#xD;
      This is a multi-center, double blind, randomized control trial designed to assess the safety&#xD;
      and efficacy of daily NB-UVB light for patients presenting to site hospitals over the age of&#xD;
      50 with a positive COVID-19 panel and at least one comorbidity.&#xD;
&#xD;
      This trial provides adjunctive therapy and no in-hospital treatments need to be modified in&#xD;
      any way. The sponsor and the centers acknowledge standards of care are actively evolving and&#xD;
      this trial is not intended to interfere in any form.&#xD;
&#xD;
      Double Blind: Patient and Health care provider will be blinded to the treatment vs. placebo&#xD;
      by use of a non-NB-UVB light card. All dosing and times for treatment and placebo will be&#xD;
      calculated the same methods.&#xD;
&#xD;
      Arm A: Control: Will receive non-NB-UVB light during the Treatment Period.&#xD;
&#xD;
      Arm B: Treatment: Will receive NB-UVB light during the Treatment Period.&#xD;
&#xD;
      Treatment Phase (Days 1-8): Treatment Schedule will be identical for arm A and B.&#xD;
&#xD;
      Follow Up Phase (Days 9-28 or discharge): Follow-up will be identical for arms A and B.&#xD;
&#xD;
      Blood Draw Schedule: Blood draws are to be performed after enrollment, before the first&#xD;
      treatment day 1 and on days 3, 5, 8, 14 and day of discharge (if prior to day 14 unless blood&#xD;
      draw has already occurred within one day of discharge).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 Randomized Placebo Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>14 days</time_frame>
    <description>% Patient Mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>28 days</time_frame>
    <description>% Patient Mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO Ordinal Scale for Clinical Improvement</measure>
    <time_frame>14 days</time_frame>
    <description>Improvement in WHO Ordinal Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO Ordinal Scale for Clinical Improvement</measure>
    <time_frame>28 days</time_frame>
    <description>Improvement in WHO Ordinal Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>28 days</time_frame>
    <description>Days from Treatment to Discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Escalation to the ICU</measure>
    <time_frame>day 14</time_frame>
    <description>% of Patients Escalating to the ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Ventilator Support (intubation) requirement</measure>
    <time_frame>day 28</time_frame>
    <description>% of Patients Requiring Ventilator Support (intubation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Improved Immune Regulation as measured by (Any 3 of These):</measure>
    <time_frame>28 days</time_frame>
    <description>Increased ratio of CD8 perforin to Monocyte IL6,&#xD;
Increased ratio ofNK perforin to Monocyte IL6&#xD;
Increased ratio of CD4 lFNg to Monocyte IL6&#xD;
Increased ratio of CD8 perforin to Monocyte TNF&#xD;
Increased ratio ofNK perforin to Monocyte TNF, and&#xD;
Increased ratio of CD4 IFNg to Monocyte TNF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Stabilization of the Immune Dysregulation (all 3 of These)</measure>
    <time_frame>28 days</time_frame>
    <description>Decreased Th l and Th 17;&#xD;
Increased Th2;&#xD;
Increased circulating regulatory T Cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Reduction in Inflammatory Markers:</measure>
    <time_frame>28 days</time_frame>
    <description>HS-CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Reduction in Inflammatory Markers:</measure>
    <time_frame>28 days</time_frame>
    <description>LDH (units per liter (U/L))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Reduction in Inflammatory Markers:</measure>
    <time_frame>28 days</time_frame>
    <description>Ferritin (micrograms/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Hemostatic Regulation by D-dimer Reduction</measure>
    <time_frame>28 days</time_frame>
    <description>D-dimer (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Hemostatic Regulation by reduce PTT</measure>
    <time_frame>28 days</time_frame>
    <description>Partial Thromboplastin Time (PTT) Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Reduced Viral Load.</measure>
    <time_frame>28 days</time_frame>
    <description>Reduced viral load (copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average and Categorical Increase in Vitamin D:</measure>
    <time_frame>28 days</time_frame>
    <description>25(OH)D hydroxyvitamin D&#xD;
1. % of Patients Improving from Critical Deficiency (min. of 20ng/ml); ii. % of Patients Improving from Insufficiency (at min. of 30ng/ml);&#xD;
Active 1,25-dihydroxyvitamin D and&#xD;
i. % of Patients with Improvement from Insufficient (at min. of 18pg/ml);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Patients with a Change in oxygen requirement</measure>
    <time_frame>28 days</time_frame>
    <description>Non-invasive positive pressure support (BiPAP &amp; CPAP)&#xD;
Discharge from the ICU&#xD;
Removal from Ventilator Support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Temperature</measure>
    <time_frame>28 days</time_frame>
    <description>(Average for each day) - Hospital Staff&#xD;
(Highest Record of the day) - Hospital Staff</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Length of Hospitalization</measure>
    <time_frame>28 days</time_frame>
    <description>Days in the ICU Days to Discharge Need for Rehospitalization Need for COVID Related Rehospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Coagulation Disorder, Blood</condition>
  <arm_group>
    <arm_group_label>Phototherapy of narrow band ultraviolet Light B-Band NB-UVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anthem One, AOMI Lights UVB nano-LED phototherapy device that emits UVB between 280nm and 320nm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Light</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same Anthem One, AOMI Lights, with different nano-LED's that do not emit UVB light between 280nm and 320 nm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narrow Band ultraviolet B-Band Light</intervention_name>
    <description>Daily doses of NB-UVB for 8 consecutive days.</description>
    <arm_group_label>Phototherapy of narrow band ultraviolet Light B-Band NB-UVB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>non Narrow Band ultraviolet B-Band Light</intervention_name>
    <description>Daily doses of non-NB-UVB for 8 consecutive days.</description>
    <arm_group_label>Placebo - Light</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible to enroll in the study, subjects must be:&#xD;
&#xD;
          -  In-Hospital&#xD;
&#xD;
          -  50 years of age or older&#xD;
&#xD;
          -  Hospitalized for COVID-I9 symptoms&#xD;
&#xD;
          -  At least one comorbidity.&#xD;
&#xD;
          -  They have taken a COVID-19 diagnostic test.&#xD;
&#xD;
          -  Peripheral 02 saturation below 94 on room air, nasal cannula or&#xD;
&#xD;
          -  non-rebreather&#xD;
&#xD;
          -  Patients may remain enrolled as long as they remain hospitalized for&#xD;
&#xD;
          -  COVID-19 symptoms and receive a positive test panel for COVID-19&#xD;
&#xD;
          -  during the treatment phase&#xD;
&#xD;
          -  Be able to provide consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        To be eligible to enroll in the study, subjects must not:&#xD;
&#xD;
          -  Require ventilatory support at the time of enrollment.&#xD;
&#xD;
          -  Concurrent pulmonary bacterial infection&#xD;
&#xD;
          -  Taking Light Sensitive Medications&#xD;
&#xD;
          -  Have Lupus Diagnosis&#xD;
&#xD;
          -  Enrolled in an existing Covid-19 Trial&#xD;
&#xD;
          -  Taking In-patient Vitamin oral Supplementation&#xD;
&#xD;
          -  Severe mental or medical disability&#xD;
&#xD;
          -  History of melanoma or dysplastic nevus syndrome&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  Active tuberculosis or Cystic Fibrosis, Severe Chronic Obstructive Pulmonary Disease&#xD;
             (COPD) or Pulmonary Fibrosis requiring home supplemental oxygen&#xD;
&#xD;
          -  Pre-existing pulmonary hypertension&#xD;
&#xD;
          -  INR &gt; 2, LFT 6 times greater than baseline&#xD;
&#xD;
          -  Stage 3b CKD or ESRD diagnosis before COVID-19 onset&#xD;
&#xD;
          -  Evidence of cirrhosis&#xD;
&#xD;
          -  Evidence of pre-existing vascular disorder or coagulopathy&#xD;
&#xD;
          -  Irreversible bleeding disorder&#xD;
&#xD;
          -  Patients who are not full code&#xD;
&#xD;
          -  Taking oral light sensitizing medications (See Appendix) or using light sensitizing&#xD;
             topical&#xD;
&#xD;
          -  medication in the phototherapy treatment zones&#xD;
&#xD;
          -  Taking in patient or at home Vitamin D supplementation&#xD;
&#xD;
          -  Have any photosensitive skin disorder such as Systemic Lupus Erythematosus, Porphyria&#xD;
             or&#xD;
&#xD;
          -  Pseudoporphyria, Polymorphous Light Eruption Xeroderma Pigmentosa, Chronic actinic&#xD;
&#xD;
          -  dermatitis, Hydroa vacciniforme, Dermatomyositis Bloom Syndrome, Rothmund Thomas&#xD;
&#xD;
          -  syndrome, Cockayne Syndrome&#xD;
&#xD;
          -  Requiring oxygen supplementation via CPAP/BiPAP, ventilator support, High Flow Nasal&#xD;
&#xD;
          -  Prong therapy (HFNP)&#xD;
&#xD;
          -  Concurrent pulmonary bacterial infection at the time of enrollment&#xD;
&#xD;
          -  Previous hospital admission for COVID-19 symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank H Lau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana State University Health Sciences Center in New Orleans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank H Lau, MD</last_name>
    <phone>504-412-1240</phone>
    <email>flau@lsuhsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ann D McKendrick, MSW</last_name>
    <phone>504-251-3924</phone>
    <email>amcken@lsuhsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Jefferson Medical Center and LSUHSC-NO</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Frank H Lau, MD</last_name>
      <phone>504-412-1240</phone>
      <email>flau@lsuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ann D McKendrick, MSW</last_name>
      <phone>504-251-3924</phone>
      <email>amcken@lsuhsc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Narrow Band Ultraviolet Light B-Band</keyword>
  <keyword>NB-UVB</keyword>
  <keyword>Immune Dysregulation</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

